275 related articles for article (PubMed ID: 26682993)
1. Determinants of Onset of Huntington's Disease with Behavioral Symptoms: Insight from 92 Patients.
Lenka A; Kamble NL; Sowmya V; Jhunjhunwala K; Yadav R; Netravathi M; Kandasamy M; Moily NS; Purushottam M; Jain S; Pal PK
J Huntingtons Dis; 2015; 4(4):319-24. PubMed ID: 26682993
[TBL] [Abstract][Full Text] [Related]
2. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.
Fusilli C; Migliore S; Mazza T; Consoli F; De Luca A; Barbagallo G; Ciammola A; Gatto EM; Cesarini M; Etcheverry JL; Parisi V; Al-Oraimi M; Al-Harrasi S; Al-Salmi Q; Marano M; Vonsattel JG; Sabatini U; Landwehrmeyer GB; Squitieri F
Lancet Neurol; 2018 Nov; 17(11):986-993. PubMed ID: 30243861
[TBL] [Abstract][Full Text] [Related]
3. Clinical and genetic characteristics in patients with Huntington's disease from China.
Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF
Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361
[TBL] [Abstract][Full Text] [Related]
4. Familial aggregation of psychotic symptoms in Huntington's disease.
Tsuang D; Almqvist EW; Lipe H; Strgar F; DiGiacomo L; Hoff D; Eugenio C; Hayden MR; Bird TD
Am J Psychiatry; 2000 Dec; 157(12):1955-9. PubMed ID: 11097960
[TBL] [Abstract][Full Text] [Related]
5. Preliminary analysis of Huntington's Disease in South Korea.
Shin CW; Choi YJ; Kim M; Jeon BS
J Huntingtons Dis; 2013; 2(1):83-7. PubMed ID: 25063431
[TBL] [Abstract][Full Text] [Related]
6. Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing.
Ramos-Arroyo MA; Moreno S; Valiente A
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):337-42. PubMed ID: 15716522
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Family History on the Clinical Features of Huntington's Disease.
Kringlen G; Kinsley L; Aufox S; Rouleau G; Bega D
J Huntingtons Dis; 2017; 6(4):327-335. PubMed ID: 28984613
[TBL] [Abstract][Full Text] [Related]
8. Late-onset Huntington's disease with 40-42 CAG expansion.
Capiluppi E; Romano L; Rebora P; Nanetti L; Castaldo A; Gellera C; Mariotti C; Macerollo A; Cislaghi MG
Neurol Sci; 2020 Apr; 41(4):869-876. PubMed ID: 31820322
[TBL] [Abstract][Full Text] [Related]
9. Clinical and genetic characteristics in patients with Huntington's Disease from Argentina.
Gatto E; Parisi V; Persi G; Converso DP; Etcheverry JL; Varela V; Lopez A; Alba L; Fretchel G
Parkinsonism Relat Disord; 2012 Feb; 18(2):166-9. PubMed ID: 21962718
[TBL] [Abstract][Full Text] [Related]
10. Exploring the correlates of intermediate CAG repeats in Huntington disease.
Ha AD; Jankovic J
Postgrad Med; 2011 Sep; 123(5):116-21. PubMed ID: 21904093
[TBL] [Abstract][Full Text] [Related]
11. Huntington's disease in Turkey: genetic counseling, clinical features, and outcome.
Karadag YS; Cavdarli BE; Yuksel RN
Neurol Res; 2021 May; 43(5):381-386. PubMed ID: 33377823
[No Abstract] [Full Text] [Related]
12. The number of CAG repeats within the normal allele does not influence the age of onset in Huntington's disease.
Klempíř J; Zidovská J; Stochl J; Ing VK; Uhrová T; Roth J
Mov Disord; 2011 Jan; 26(1):125-9. PubMed ID: 21322024
[TBL] [Abstract][Full Text] [Related]
13. Age of onset and behavioral manifestations in Huntington's disease: An Enroll-HD cohort analysis.
Ranganathan M; Kostyk SK; Allain DC; Race JA; Daley AM
Clin Genet; 2021 Jan; 99(1):133-142. PubMed ID: 33020896
[TBL] [Abstract][Full Text] [Related]
14. Weight loss in Huntington disease increases with higher CAG repeat number.
Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for the onset and progression of Huntington disease.
Chao TK; Hu J; Pringsheim T
Neurotoxicology; 2017 Jul; 61():79-99. PubMed ID: 28111121
[TBL] [Abstract][Full Text] [Related]
16. Severity of cognitive impairment in juvenile and late-onset Huntington disease.
Gómez-Tortosa E; del Barrio A; García Ruiz PJ; Pernaute RS; Benítez J; Barroso A; Jiménez FJ; García Yébenes J
Arch Neurol; 1998 Jun; 55(6):835-43. PubMed ID: 9626775
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory Strategies for Huntington's Disease Treatment.
Colpo GD; Rocha NP; Stimming EF; Teixeira AL
CNS Neurol Disord Drug Targets; 2017; 16(8):936-944. PubMed ID: 28606048
[TBL] [Abstract][Full Text] [Related]
18. Effect of Apolipoprotein E Genotypes on Huntington's Disease Phenotypes in a Han Chinese Population.
Li XY; Zhang YB; Xu M; Cheng HR; Dong Y; Ni W; Li HL; Wu ZY
Neurosci Bull; 2019 Aug; 35(4):756-762. PubMed ID: 30887245
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of molecular testing in Huntington's disease.
Wang V; Yeh TP; Chen CM; Yan SH; Soong BW
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Sep; 62(9):586-90. PubMed ID: 10502848
[TBL] [Abstract][Full Text] [Related]
20. Nonparametric modeling and analysis of association between Huntington's disease onset and CAG repeats.
Ma Y; Wang Y
Stat Med; 2014 Apr; 33(8):1369-82. PubMed ID: 24027120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
